Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Oncoimmunology|January 27, 2022
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1Dafne C A Quixabeira, Victor Cervera-Carrascon, Joao M Santos, et al.
Frontiers in Immunology|July 21, 2023
An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippageSanteri Pakola, Dafne C A Quixabeira, Tatiana V Kudling, et al.
Molecular Therapy Oncolytics|January 26, 2023
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumorsSaru Basnet, Joao M Santos, Dafne C A Quixabeira, et al.
Frontiers in Immunology|March 31, 2022
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck CancerJames H A Clubb, Tatiana V Kudling, Camilla Heiniö, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 24, 2024
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokineSaru Basnet, Mirte Van der Heijden, Dafne C A Quixabeira, et al.
Molecular Therapy Oncolytics|April 24, 2020
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid TumorsVictor Cervera-Carrascon, Dafne C A Quixabeira, Riikka Havunen, et al.
Molecular Therapy. Oncology|July 1, 2025
Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinomaVictor Arias, Tatiana V Kudling, James H A Clubb, et al.
Journal for Immunotherapy of Cancer|January 27, 2025
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trialSanteri A Pakola, James H A Clubb, Tatiana V Kudling, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2025
Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer modelsSanteri A Pakola, Nea Ojala, Tatiana V Kudling, et al.
Cancer Gene Therapy|April 10, 2025
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomesTatiana V Kudling, Dmitrii Bychkov, James H A Clubb, et al.
Pageof 2